5/22/2021 COVID-19: Current coronavirus vaccines unlikely to protect against new variants in future, SAGE warnsRead NowThe government's scientific advisers say COVID may continue to evolve for years to come and "eradication is extremely unlikely". Current COVID-19 vaccines are unlikely to protect against new variants of the virus in the future, the government's scientific advisers have warned. In a paper published on Friday, the Scientific Advisory Group for Emergencies (SAGE) said coronavirus may continue to evolve for years to come and that "eradication is extremely unlikely". The experts warn that eventually it is likely "current vaccines will fail to protect against transmission, infection, or even against disease caused by newer variants". Read the full article here.
0 Comments
The World Health Organization (WHO) has granted emergency approval for a Covid vaccine made by Chinese state-owned company Sinopharm. It is the first vaccine developed by a non-Western country to get WHO backing. The vaccine has already been given to millions of people in China and elsewhere. The WHO had previously only approved the vaccines made by Pfizer, AstraZeneca, Johnson & Johnson and Moderna. But individual health regulators in various countries - especially poorer ones in Africa, Latin America and Asia - have approved Chinese jabs for emergency use. With little data released internationally early on, the effectiveness of the various Chinese vaccines has long been uncertain. But the WHO on Friday said it had validated the "safety, efficacy and quality" of the Sinopharm jab developed by the Beijing Institute of Biological Products. The WHO said the addition of the vaccine had "the potential to rapidly accelerate Covid-19 vaccine access for countries seeking to protect health workers and populations at risk". It is recommending that the vaccine be administered in two doses to those aged 18 and over. A decision is expected in the coming days on another Chinese vaccine developed by Sinovac, while Russia's Sputnik vaccine is under assessment. Read the full article here. |
Details
Categories
All
Archives
April 2023
|